Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Shares Issued (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Shares Issued for 9 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Shares Issued rose 100.67% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.5 million through Dec 2025, down 51.35% year-over-year, with the annual reading at $8.5 million for FY2025, 51.35% down from the prior year.
  • Shares Issued for Q4 2025 was $3.2 million at Denali Therapeutics, down from $5.2 million in the prior quarter.
  • The five-year high for Shares Issued was $499.3 million in Q1 2024, with the low at -$491.5 million in Q2 2024.
  • Average Shares Issued over 5 years is $18.9 million, with a median of $4.4 million recorded in 2022.
  • Peak annual rise in Shares Issued hit 19622.11% in 2024, while the deepest fall reached 10341.53% in 2024.
  • Over 5 years, Shares Issued stood at $5.2 million in 2021, then skyrocketed by 5418.5% to $285.2 million in 2022, then crashed by 98.35% to $4.7 million in 2023, then plummeted by 10341.53% to -$481.9 million in 2024, then soared by 100.67% to $3.2 million in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at $3.2 million, $5.2 million, and -$595000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.